Similar studies have also demonstrated that B029-2, which regulates the acetylation of H3 K18 and K27, reduces the glycolytic capacity of hepatocellular carcinoma cells; thus, it has been explored as a potential p300-targeting drug for cancer treatment [71]. This evidence concerns the gene EP300 and cancer.